Cipla

1. Assignment no.1
On
CIPLA LTD CO.
Submitted by : Submitted to :
Sarita kumari Mrs. Rajni Madam
Roll no. -50
DESH BHAGAT UNVERSITY
OF MANGEMENT AND COMPUTER SCIENCE

2. WHO IS CIPLA &WHAT DO THEY DO
WHO
1. The Chemical, Industrial & Pharmaceutical Laboratories;
2. Founded by Khwaja Abdul Hamid in the year 1935; and
3. On August 17,1935, Cipla was registered as a public
limited company.
WHAT
1. Today Cipla is a leading player in anti-infective and
anti- asthmatic formulation;
2. Specializes in the manufacturing of steroids and
hormones ; and
3. Cipla has time and again earned the distinction of
coming out with pioneering and life saving drugs.

3. Listings and shareholding
Shareholders (as on 30-September-2013) Shareholding
Promoter Group 36.80%
Foreign Institutional Investors (FII) 23.78%
Individual shareholders 18.67%
Insurance companies 06.59%
Private Corporate Bodies 05.11%
Mutual Funds and UTI 04.11%
NRI/FCB/Others 03.90%
GDRs 01.04%
Total 100.0%

4. Cipla Products
Sales Value (in Cr)
• Tablets n Capsules 3981.31
• Bulk Drugs 897.8
• Aerosols 617.48
• Liquids 512.5
• Creams 134.04
• Others 86.78
• Export Incentives 80.95
• Other services 31.03
• Sale of services 27.01
• Scrap 25.54

5. STP – Cipla Ltd
Segment HIV/AIDS, cancer, arthritis, respiratory,
cardiovascular disease
Target Group Flavors and fragrances, OTC, prescription
products, pesticides, agrochemicals
Positioning Developing life saving drugs
SWOT Analysis – Cipla Ltd
Strength 1. Has developed good positive image by providing
support to cancer patients by issuing drugs at low
cost
2. Imminent commencement of the Fixed-Dose
combination for treatment of uncomplicated malaria
to tackle the 200+ million cases globally
3. Initiation of „No Touch Breast Scan‟ a step forward in
the screening technology in India.

6. Weakness 1. Strong competition from
international and domestic
giants means limited market
share 2. Had faced problems
during negative campaign by AHF
Opportunity 1. Can venture into Alzheimer‟s
disease medication
2. Increased investment in the
budding markets, to push
expansion in the global
economy
Threats 1. Constant price rises in India
2. Depreciation of Indian Rupee as
compared to US Dollar -
Fluctuations in currency
exchange rates

7. GAP Analysis of Cipla
LOCATION: African market is the major market,followed
by US. It has also discovered Europe as a high potential
market.
PRODUCT: Growth in domestic formulation is 12% -
farbelow the industry average
RESEARCH: It‟s APIs are still about to reap benefitsand are
expected to grow after a few years

8. Mission and Vision CIPLA Ltd
• Mission - “To provide excellent quality health care
facilities at reasonable cost”
• Vision – To build a healthier and hence, better,
world. Unichem Labs
• Mission - “To be a caring pharmaceutical company
helping to enhance health through quality products”
• Vision - "To be a global pharmaceutical company with
increasing focus on innovative research and
developed markets."

9. • Raw materials – Backward Integration as well as
horizontal Integration
• Low Debt/Equity Ratio of Unichem
• Strong Subsidiary in European Market – Niche
Generics
• Rich US pipeline - Unichem Pharmaceuticals (USA)
Inc. – several ANDA in pipeline
• Presence across diversified therapeutic classes

10. APPLICABILITY
• The Corporate Social Responsibility (CSR) Policy
of Cipla Limited (“Company”) has been framed
and made applicable in accordance with section
135 of the Act read with the Rules.
• The Policy shall apply to the CSR Committee and
all CSR projects/programmes undertaken by the
Company in accordance with Schedule VII of the
Act.

11. Corporate Social Responsibility (CSR)
CSR COMMITTEE
• CSR Committee of the Board has been formed as required under the Act.
CSR EXPENDITURE
• CSR expenditure shall include all expenditure including contribution
to corpus, for projects or programmes relating to CSR activities
approved by the Board on the recommendation of the CSR
Committee, but does not include any expenditure on an item not in
conformity or not in line with activities which fall within the
purview of the Schedule VII of the Act.
EXECUTION, MONITORING & REPORTING
The CSR Committee shall:
• Prepare and propose the CSR plan with the execution modalities and
implementation schedules to the Board.
• Periodically appraise the Board on the status of the CSR plan.
• Institute a transparent monitoring mechanism for implementation of the
CSR projects, programmes or activities undertaken by the Company.